
Bristol-Myers Squibb Company

BMY (Bristol-Myers Squibb Company) trades at 3.3x EV/Revenue — attractively valued for a healthcare & pharma company with strong gross margins (68%) and mature growth profile. The business is highly profitable at 30% EBIT margins. Forward PE of 9x.
A stock trading at 2x EV/Revenue with 30% growth is cheaper than one at 5x with 10% growth — growth-adjusted valuation matters.
Gold Eagle provides data and AI-generated analysis for informational purposes only. Not investment advice. All data from public sources.
Bristol Myers Squibb is a global biopharmaceutical company that discovers, develops, and commercializes innovative medicines for serious diseases, particularly cancer, immunology, and cardiovascular conditions. They serve patients worldwide through a portfolio of prescription drugs sold to hospitals, clinics, and pharmacies, generating revenue primarily from drug sales and licensing agreements. The company focuses on transformative therapies that address significant unmet medical needs.
BMY is navigating a transition period where newer growth drivers must offset patent expirations of legacy blockbusters. The company is targeting mid-single-digit revenue growth over the next five years, driven by expansion of newer oncology franchises and successful launches from their deep pipeline. Key growth catalysts include geographic expansion of existing drugs and breakthrough designations for novel therapies in large addressable markets.
Bristol Myers maintains healthy gross margins of approximately 75% typical of branded pharmaceuticals, though operating margins face pressure from increased R&D spending and generic competition. The company generates strong free cash flow of $6-8 billion annually, supporting both reinvestment in innovation and consistent capital returns to shareholders. Margin expansion depends on successful new drug launches outpacing patent cliff impacts.
BMY competes with pharmaceutical giants like Merck, Roche, and Johnson & Johnson in oncology and specialty therapeutics. The company differentiates through its immuno-oncology expertise and focus on combination therapies, though it faces intense competition in key markets. Their CAR-T cell therapy capabilities and strong relationships with oncologists provide defensive moats in select therapeutic areas.
*Note: Specific recent quarter details are not available in the provided data, limiting detailed momentum analysis.*
The company continues executing on its strategy to diversify revenue sources and advance pipeline assets through clinical development. Market focus remains on new drug approval timelines and competitive positioning in key therapeutic areas.
*Note: Current analyst sentiment data is not available in the provided information.*
The investment community typically focuses on BMY's ability to successfully transition through patent cliffs while delivering pipeline value. Key debates likely center on the timing and magnitude of new drug contributions versus legacy product declines.
Bristol Myers Squibb is a dividend-paying pharmaceutical stock offering exposure to innovation in high-value therapeutic areas, but investors must weigh the company's pipeline potential against near-term headwinds from patent cliff pressures.
Pre-generated investor questions answered by Claude Opus. Available in the Atlas AI tab.








| '25E | '26E | '27E | '28E | |
|---|---|---|---|---|
| Revenue | — | $46.9B | $46.0B | $40.8B |
| Growth | — | (2%) | (11%) | |
| EBITDA | — | $15.5B | $15.2B | $13.4B |
| Growth | — | (2%) | (11%) | |
| EPS (PF) | — | $6.26 | $6.13 | $5.45 |
| Growth | — |
Bristol Myers Squibb Transforms the Classical Hodgkin Lymphoma Treatment Paradigm with Expanded U.S. and EMA Approvals for Opdivo® (nivolumab)
Bristol Myers Secures FDA Nod For Opdivo Plus Chemo For Untreated Hodgkin Lymphoma
US FDA approves Bristol Myers Squibb's cancer drug for Hodgkin's lymphoma
Bristol Myers Squibb to Report Results for First Quarter 2026 on April 30, 2026
TrumpRx lists many medicines at prices higher than paid in UK
| (2%) |
| (11%) |